Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Itnogen** is a 20 mg/g (2%) transdermal testosterone gel formulation used as testosterone replacement therapy in adult men with male hypogonadism, confirmed by two separate blood testosterone measurements and clinical symptoms such as impotence, infertility, low sex drive, tiredness, depressive moods, and bone loss. The active ingredient, testosterone, is an androgen hormone responsible for male sex organ development and secondary sex characteristics. Applied topically once daily to the abdomen or inner thighs via a metered-dose pump (starting dose 3 g gel containing 60 mg testosterone, adjustable up to 4 g/80 mg), it restores serum testosterone to normal levels (300-1140 ng/dL) while minimizing risks like skin transfer to others.[1][4][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Itnogen.